Furthermore, in participants with T2D, treatment with the selective long-acting GIP receptor agonist, macupatide, was associated with a larger insulin sensitivity improvement compared with the selective GLP-1 receptor agonist dulaglutide, despite similar body weight reduction, and combination therapy with these agents was associated with additive effects on insulin sensitivity [20]
Confusion grows when trial data, real-world experiences, and medical advice seem to contradict each other
If youre comparing Semaglutide and Tirzepatide, the best fit depends on your medical history, weight-loss goals, tolerance, budget, and provider recommendation
ART treatment upregulated ROS, Fe 2+ , and lipid peroxidation levels while suppressing MM cell growth, concomitant with increased ACSL4 expression and decreased GPX4 levels
The control group received no GLP-1 agonist therapy and consisted of 12 patients